Conversely, targeting in vitro HER2+ BC cells with either one or the other agent has only minor effects in CDC, whereas combination therapy neutralizes complement regulatory proteins (such as CD46, CD55, and CD59) followed by an antibody-induced C3 opsonization and killing of tumour cells [78,79]. Here, ERBB2 is linked to neoplasm.